Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab-Reference-Cited by-同舟云学术

Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab

Published:2016-11-08 Issue:1 Volume:6 Page:11-20
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst. Pharmacol.

Author:

Lindauer A¹,Valiathan CR¹,Mehta K¹,Sriram V¹,de Greef R¹,Elassaiss-Schaap J¹,de Alwis DP¹

Affiliation:

1. Merck & Co., Inc.; Rahway New Jersey USA

Publisher

Wiley

Subject

Pharmacology (medical),Modelling and Simulation

Reference26 articles.

1. Mechanisms of immune evasion by tumors;Drake;Adv. Immunol.,2006

2. The blockade of immune checkpoints in cancer immunotherapy;Pardoll;Nat. Rev. Cancer,2012

3. Tumor immunotherapy directed at PD-1;Ribas;N. Engl. J. Med.,2012

4. Immune regulation of cancer;Disis;J. Clin. Oncol.,2010

5. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N. Engl. J. Med.,2010

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: A nationwide retrospective cohort study with a non-inferiority primary objective;Lung Cancer;2024-10

2. Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer;Molecular Cancer;2024-08-02

3. Disentangling Anti‐Tumor Response of Immunotherapy Combinations: A Physiologically Based Framework for V937 Oncolytic Virus and Pembrolizumab;Clinical Pharmacology & Therapeutics;2024-07-22

4. A comprehensive review of computational cell cycle models in guiding cancer treatment strategies;npj Systems Biology and Applications;2024-07-05

5. Utility and impact of quantitative pharmacology on dose selection and clinical development of immuno-oncology therapy;Cancer Chemotherapy and Pharmacology;2024-03-02